News

“Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.”

In the prospective, non-interventional SUSTAIN study, patients with active psoriatic arthritis received ustekinumab for 3 years in routine clinical care.

“Kinesiophobia plays a major role in the onset, persistence, and exacerbation of chronic disability in a variety of musculoskeletal disorders."

"Lupus nephritis (LN) patients might suffer from mental disorders which further prolong the LN treatment duration and affect patients' quality of life.”

Can women with rheumatoid arthritis (RA) continue their treatment if they become pregnant or should they stop or change therapy to protect their unborn child? Test your knowledge with this quiz.

Rheumatology Network's month in review spotlights the most popular content from the past month.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 3, 2022.

"The high prevalence of severe infection in newly diagnosed SLE implies that infections may be related to the underlying immune disturbance of SLE itself.”

"Sex may play an underlying role in driving the mechanisms of psoriatic arthritis, leading to different clinical manifestations of the disease," investigators theorized.

Fibromyalgia patients have 3 times the rate of depression compared with those without the condition and more than 50% of patients with fibromyalgia experience lifetime depression.

"Comprehensively defining the risk of melanoma associated with low-dose methotrexate is important for clinicians across several medical disciplines."

Previous renal response endpoints used in lupus nephritis trials lacked uniformity and their accuracy of long-term kidney survival prediction was questionable.

Machine learning algorithms identify patterns without being explicitly programmed to do so, which allows for unbiased discoveries.

Although effective therapies are crucial, adverse events, financial burden, and other factors make a "taper-to-target" approach appealing to both pediatric patients and their caregivers.

Although investigations have been performed on the association between inflammatory conditions and cardiovascular events, the effect of different conditions on cardiovascular diseases has not been analyzed on a large scale.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 27, 2022.

"This risk-to-benefit profile has a different connotation for patients because, although a therapy may improve certain aspects of their disease, it may also have a substantial impact on their quality of life.”

Rheumatology Network interviewed Paul M. Peloso, MD, MSc, Chief Medical Officer at Acelyrin, to discuss recent phase 2 data examining the safety and efficacy of izokibep in the treatment of psoriatic arthritis.

Demographic factors and comorbidities are associated with death related to COVID-19 in the general population and in people with rheumatic diseases, including gout.

"Cardiovascular manifestations in rheumatoid arthritis can be complex, raising concerns for adequate patient management and provider-dependent roles.”

Although pulmonary complications in pediatric patients may cause functional impairment and increase mortality, studies detecting lung involvement in children with treatment-naïve, newly diagnosed patients with rheumatic disease are scarce.

Investigators believe that “screening for comorbidities of COPD and diabetes mellitus with end-organ damage as part of the routine in treating RA-ILD population" may be beneficial.

An observational cross-sectional study finds that patients suffering from such inflammatory conditions had a higher average number of missing teeth compared to the control group.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 20, 2022.

"Chronic cutaneous lupus erythematosus is prone to cause substantial disfigurement on visible skin, negatively impacting patients’ mental health and social life."

“These observations suggest that the often-observed epidemiologic correlation between low serum urate and adverse health outcomes may be confounded."

Although the role of PPIs in the occurrence of both drug-induced systemic lupus erythematosus and drug-induced cutaneous lupus erythematosus has been suggested, it remains poorly characterized.

The US Food and Drug Administration approved of the citrate-free, high-concntration (100 mg/mL) formulation of adalimumab-bwwd, a biosimilar of adalimumab, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

“Given the complex nature of PsA, patients should also be involved in defining their treatment goals, as every patient may have different perspectives on the target for therapy and the means to achieve it.”

Although the current treatment strategies for children with juvenile idiopathic arthritis help to relieve pain symptoms, these medications provide limited efficacy on the underlying disease.